RELA

RELA Full Name

v-rel avian reticuloendotheliosis viral oncogene homolog A

RELA Introduction

NF-κB Signaling Pathway subunit RELA, also known as p65, is one of the most extensively studied transcriptional regulators involved in inflammation, immunity, cell survival, and cancer progression. Researchers and pharmaceutical developers continue to focus on RELA because dysregulated NF-κB signaling is closely associated with chronic inflammatory diseases, immune imbalance, tumor metastasis, and resistance to therapy. Under normal physiological conditions, RELA is retained in the cytoplasm through interaction with inhibitory proteins. Once cells are exposed to inflammatory cytokines, oxidative stress, infection, or DNA damage, RELA rapidly translocates into the nucleus and activates genes responsible for immune defense, proliferation, apoptosis resistance, and cytokine production. Due to its broad regulatory influence across multiple cellular pathways, RELA has become an important therapeutic target in both oncology and inflammatory disease research.

One of the major difficulties in targeting RELA clinically is that NF-κB signaling performs both protective and disease-promoting functions depending on the cellular environment. Recent advances in molecular biology have shown that RELA operates within highly dynamic protein interaction networks involving transcription factors, chromatin remodeling complexes, and epigenetic regulators. These interactions help determine how inflammatory genes are activated under different stress conditions. Studies have demonstrated that RELA activity relies heavily on proper dimerization and coordinated interactions with multiple cofactors that regulate immune and stress-response pathways. Beyond inflammation and cancer, RELA also plays a critical role in stem cell biology and developmental regulation. Dynamic p65 signaling patterns have been shown to influence hematopoietic stem and progenitor cell progression through cell-cycle control, highlighting the importance of precisely regulated inflammatory signaling during tissue development and regeneration.

Abnormal RELA activation has been linked to a wide range of diseases, including rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, neurodegenerative diseases, and many forms of cancer. Particularly significant is the discovery of RELA fusion-driven ependymoma, an aggressive subtype of brain tumor commonly found in pediatric patients. In these tumors, fusion proteins involving RELA lead to constitutive activation of NF-κB signaling, allowing continuous expression of oncogenic target genes that promote tumor growth, survival, and poor clinical outcomes. Persistent RELA signaling is also associated with tumor invasion, angiogenesis, immune evasion, and resistance to chemotherapy or radiation therapy in multiple cancer types. As precision medicine and molecular diagnostics continue to advance, RELA is increasingly recognized not only as a biomarker for disease classification and prognosis, but also as a promising target for next-generation anti-inflammatory drugs, immunotherapies, and targeted cancer treatment strategies.

Alternate Names for RELA

RELA; v-rel avian reticuloendotheliosis viral oncogene homolog A; p65; NFKB3; transcription factor p65; NF-kappa-B p65delta3; nuclear factor NF-kappa-B p65 subunit; v-rel reticuloendotheliosis viral oncogene homolog A; nuclear factor of kappa light polypeptide gene enhancer in B-cells 3;

• 1.Leib L, et al.; The proximity-based protein interactome and regulatory logics of the transcription factor p65 NF-κB/RELA. EMBO Rep. 2025, 26(4):1144-1183.
  2.Campbell CA, et al.; p65 signaling dynamics drive the developmental progression of hematopoietic stem and progenitor cells through cell cycle regulation. Nat Commun. 2024, 15(1):7787.